56 results on '"Sjöwall C"'
Search Results
2. POS1121 ASSESSMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DISEASE ACTIVITY USING THE SLE DISEASE ACTIVITY SCORE (SLE-DAS): RESULTS FROM A SWEDISH TERTIARY REFERRAL CENTER
3. AB0577 LEFT VENTRICULAR DYSSYNCHRONY IN SUBJECTS WITH DIFFERENT SLE PHENOTYPES
4. POS0766 CIRCULATING SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (SUPAR) ASSOCIATES WITH JOINT DESTRUCTION IN JUVENILE IDIOPATHIC ARTHRITIS: A CASE-CONTROL STUDY WITH LONGITUDINAL FOLLOW-UP
5. POS1145 FACTORS ASSOCIATED WITH SURVIVAL AND DISCONTINUATION OF ANTIMALARIAL AGENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A SWEDISH LONGITUDINAL REGISTRY
6. PO.7.162 Epidemiology of systemic lupus erythematosus in central Sweden: a population-based cohort study from the östergötland county over 14 years
7. S06.1 B cell kinetics upon therapy commencement for active extra-renal systemic lupus erythematosus in relation to development of renal flares
8. PO.6.119 Low-dose belimumab and antimalarial agents prevent renal flares in systemic lupus erythematosus: results from four randomised clinical trials
9. PO.1.20 Prognostic biomarkers of organ damage in patients with newly diagnosed SLE
10. PO.4.80 Significant correlation between adjusted mean clinical sledai over time and remission defined by the doris criteria: results from a regional Swedish cohort
11. PO.7.147 Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in patients with systemic lupus erythematosus from a Swedish tertiary referral centre
12. PO.6.128 Factors associated with survival and discontinuation of antimalarial agents in systemic lupus erythematosus: results from a swedish longitudinal registry
13. PO.3.72 Extracellular vesicles opsonized by monomeric C-reactive protein are accessible as autoantigens in systemic lupus erythematosus
14. S10.2 Interaction between HLA-DRB1*03:01 and stat4 is associated with increased risk of nephritis in systemic lupus erythematosus
15. PO.7.159 Objective measures of health-related quality of life may not adequately reflect diseaseburden in systemic lupus erythematosus
16. PO.2.45 Autoantibodies associated with systemic sclerosis (SSC) in three diseases characterized by type I interferons: a comparison between SLE, primary Sjögren’s syndrome, SSC and healthy blood donors
17. PO.8.176 Inflammation in blood and placenta in SLE pregnancies
18. PO.5.110 Plasma levels of osteopontin in SLE
19. PO.4.94 High B-cell polygenic risk is associated with dsDNA antibodies and nephritis in systemic lupus erythematosus
20. Comment on ‘Systemic autoimmunity with Castleman-like lymphadenopathy: a diagnostic and therapeutic challenge’: reply
21. A rare case of idiopathic multicentric Castleman disease in a patient with long-standing systemic autoimmunity
22. Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes
23. Disease activity trajectories in rheumatoid arthritis: a tool for prediction of outcome
24. Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease
25. Secretory antibodies to citrullinated peptides in plasma and saliva from rheumatoid arthritis patients and their unaffected first-degree relatives
26. The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts
27. The diagnostic accuracies of the 2012 SLICC criteria and the proposed EULAR/ACR criteria for systemic lupus erythematosus classification are comparable
28. Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual
29. FRI0347 Performance of potential definitions of remission in systemic lupus erythematosus (SLE) versus quality of life over 5 years in swedish patients with recent-onset sle
30. OP0362 Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis
31. PS7:132 Smoking reduces the efficacy of belimumab in mucocutaneous lupus
32. PS4:71 Iga anti-phospholipid antibodies in swedish cases with systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual
33. S2A:6 Soluble urokinase plasminogen activator receptor (supar) predicts the development of organ damage over 5 years in systemic lupus erythematosus: results from the slicc inception cohort
34. Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy
35. SAT0233 High anti-dsdna content in sle immune complexes is associated with clinical remission following belimumab treatment
36. THU0663 Serum galectin-3 binding protein is a novel predictor of venous thromboembolism in patients with systemic lupus erythematosus (SLE)
37. Interferon-α coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro
38. 103 Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus
39. Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases
40. THU0345 Presence of Immunoglobulin (IG) A Antibodies against Cardiolipin and β2-Glycoprotein-I in The Absence of IGG and IGM in Systemic Lupus Erythematosus
41. OP0189 Rate of Cervical Neoplasia in Systemic Lupus Erythematosus: A Nationwide Cohort-Study: Table 1
42. International multi-center evaluation of a novel chemiluminescence assay for the detection of anti-dsDNA antibodies
43. Clinically suspected recurrence of gastric carcinoid proved to be hypocomplementaemic urticarial vasculitis syndrome with pulmonary involvement
44. No Evidence of Pathogenic Involvement of Cathelicidins in Patient Cohorts and Mouse Models of Lupus and Arthritis
45. Altered glycosylation of complexed native IgG molecules is associated with disease activity of systemic lupus erythematosus
46. FRI0172 Utility of Swedish Register Data in Classifying Systemic Lupus
47. THU0042 Autoantibodies against High Mobility Group Box Protein-1 in Systemic Lupus Erythematosus: Association with Disease Activity and Other Antinuclear Antibodies
48. Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity
49. A3.7 No evidence of cathelicidin being involved in the pathogenesis of lupus and arthritis
50. AB0697 Self-reported health and organ damage predict activity limitations in patients with systemic lupus erythematosus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.